RxDoctor Payments Data

Mohammad Saeed, MD

Psychosomatic Medicine · League City, TXNPI 1861515074

Payments from drug & device makers

$9,088in general payments, 2019–2025

Across 403 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Supernus Pharmaceuticals, Inc.$656
  • Corium, LLC$560
  • Otsuka America Pharmaceutical, Inc.$495
  • Indivior Inc.$464
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$9,04199%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychosomatic medicine providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$124,813
Medicare patients
68
Services billed
1,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate23$35,103
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl163$31,204
TrintellixVortioxetine Hydrobromide12$7,493
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$7,123
QuviviqDaridorexant Hcl12$5,550
Aripiprazole88$5,522
Lurasidone Hcl17$4,588
Doxepin Hcl63$4,215
Lisdexamfetamine Dimesylate19$4,005
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine71$3,869
Desvenlafaxine Succinate ErDesvenlafaxine Succinate82$3,136
Duloxetine Hcl148$1,500
Bupropion XlBupropion Hcl114$1,379
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,360
Hydroxyzine Hcl72$1,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,600$35,10323 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$186$7,49312 claims
Orexo US, Inc.Zubsolv$57$7,12312 claims
Idorsia Pharmaceuticals US IncQuviviq$15$5,55012 claims
Almatica Pharma LLCSertraline Hcl$32$888127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychosomatic medicine providers in Texason file to place this against a meaningful peer group, so we don't.

Other psychosomatic medicine in League City

Where these figures come from

Is this you, or does something look wrong? →